Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The ALASCA trial showed that daily low-dose aspirin reduces cancer recurrence by nearly 50% in colorectal cancer patients with specific PI3K pathway mutations. This finding suggests a need for routine molecular sequencing of early-stage tumors to identify patients for this simple, practice-changing intervention.
Related Insights
A key distinction for oncologists is that PIK3CA mutations are typically "truncal" (present from baseline), whereas ESR1 mutations are "acquired" after exposure to aromatase inhibitors. This biological difference dictates when and how to test for each biomarker throughout a patient's treatment journey.
Following the ALASKA trial, which demonstrated a disease-free survival benefit, NCCN guidelines now recommend considering aspirin for early-stage colon cancer patients with a PIK3CA mutation. This is a significant shift toward molecularly guided, non-chemotherapeutic adjuvant therapy that is not yet widely adopted.
Genomic profiling reveals PIK3CA is the most frequent mutation in anal cancer, occurring in about one-third of cases. However, unlike in other cancers, there are no effective targeted therapies for this mutation in anal cancer, creating a therapeutic dead-end and a major opportunity for drug development.
The INOVO-123 trial strategically investigates a PI3K inhibitor-based triplet therapy for endocrine-sensitive, PIK3CA-mutated breast cancer. This moves beyond its current approval in the endocrine-resistant setting, aiming to establish its efficacy for patients with de novo metastatic disease or as a first-line treatment, thereby widening its use much earlier in the patient journey.
Clinicians increasingly perform Next-Generation Sequencing (NGS) on initial diagnostic tissue, even if results don't alter first-line treatment. This proactive approach identifies stable mutations like PIK3CA early, enabling long-term planning, such as optimizing a patient's metabolic health in anticipation of future targeted therapies.
The VICTORIA-1 trial found that gedatolisib, a pan-PI3K/mTOR inhibitor, significantly improves progression-free survival in patients with PIK3CA *wild-type* tumors after CDK4/6 inhibitor progression. This is a crucial finding for a patient group lacking clear targeted options and broadens the utility of targeting the PI3K pathway beyond just mutated tumors.
For patients with a PIK3CA mutation who relapse on or shortly after adjuvant endocrine therapy, the INAVO120 trial established a new standard of care. Adding inavolisib to palbociclib and fulvestrant significantly improved overall survival by seven months, providing a potent option for this particularly high-risk, endocrine-resistant population.
Post-approval studies of the oral SERD elacestrant confirm its clinical benefit in ESR1-mutant breast cancer. However, this real-world evidence also reveals a new insight: patients who have both an ESR1 and a PIK3CA mutation tend to have a shorter time on treatment, suggesting that the PIK3CA mutation may drive resistance to this therapy.
The ALASCA trial showed aspirin halves recurrence risk in colorectal cancer patients with PI3K pathway alterations. This finding makes it critical to perform genomic sequencing on all patients, including those with non-metastatic disease, to identify the ~37% who could benefit from this simple, safe intervention.
Testing for PI3K/AKT alterations at the initial diagnosis of metastatic disease, rather than waiting for progression, provides a crucial window of time. This allows clinicians to implement proactive dietary and medical strategies to mitigate future side effects like hyperglycemia before the targeted therapy is even started.
